Chemotherapy of Human Filariasis by the Administration of Neostibosan

James T. CulbertsonDepartments of Bacteriology and of Medicine, College of Physicians and Surgeons, Columbia University, Department of Medical Zoology, School of Tropical Medicine, New York, New York

Search for other papers by James T. Culbertson in
Current site
Google Scholar
PubMed
Close
,
Harry M. RoseDepartments of Bacteriology and of Medicine, College of Physicians and Surgeons, Columbia University, Department of Medical Zoology, School of Tropical Medicine, New York, New York

Search for other papers by Harry M. Rose in
Current site
Google Scholar
PubMed
Close
, and
José Oliver-GonzalezDepartments of Bacteriology and of Medicine, College of Physicians and Surgeons, Columbia University, Department of Medical Zoology, School of Tropical Medicine, New York, New York

Search for other papers by José Oliver-Gonzalez in
Current site
Google Scholar
PubMed
Close
Restricted access

Summary and Conclusion

Thirty patients with filariasis (Wuchereria bancrofti) were treated with neostibosan for intervals ranging from 33 to 48 days. By the sixth month after treatment ended, microfilariae had disappeared from seven of the patients and had declined in all but one individual. In fifteen of the thirty treated patients, over 80 per cent of the microfilariae were lost during the six months of observation.

Among fifteen control untreated patients with filariasis, followed for the same period as those under treatment, thirteen persons showed an increase in microfilariae, one showed a small decline, and one presented no change in the number of circulating parasites.

Neostibosan has, therefore, appeared to exert a significant effect as a therapeutic agent in cases of filariasis bancrofti. It is impossible, however, as yet, to determine whether this effect is permanent, or subject to eventual relapse.

Author Notes

Read at the Fortieth Annual Meeting of the American Society of Tropical Medicine, at St. Louis, Mo. November 13–16, 1944.

Save